KING PHARMACEUTICALS (KG) Income Statement (2024 - 2026)
Income Statement report data from Jun 30, 2024 to Mar 31, 2026 for KING PHARMACEUTICALS (KG).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | Jun 30, 2024 | |
|---|---|---|---|---|---|---|
Revenue and COGS | ||||||
Total Revenue | 10M (-0.20%) | 10M (-41.49%) | 17M (+1977.38%) | 840K (+12.00%) | 750K (+19.05%) | 630K |
Operating Expenses | ||||||
Selling General And Administrative | 12M (-2.65%) | 12M (+11.87%) | 11M (+845.61%) | 1.14M (-3.39%) | 1.18M (0.00%) | 1.18M |
Operating Expenses | 4.22M (-37.11%) | 6.71M (+54.25%) | 4.35M (+663.16%) | 570K (-3.39%) | 590K (0.00%) | 590K |
Depreciation And Amortization | - | 90K | - | - | - | - |
Operating Income | ||||||
Ebit | -7.42M (-58.29%) | -17.79M (+252.28%) | -5.05M (+1583.33%) | -300.00K (-30.23%) | -430.00K (-21.82%) | -550.00K |
EBITDA | -7.42M (-58.06%) | -17.69M (+250.30%) | -5.05M (+1583.33%) | -300.00K (-30.23%) | -430.00K (-21.82%) | -550.00K |
Net Income | ||||||
Income Before Tax | - | -20.82M | - | - | - | -550.00K |
Income Tax Expense | 10K | -30.00K | 10K (-88.89%) | 90K | - | - |
Net Income From Continuing Operations | -7.43M (-58.14%) | -17.75M (+251.49%) | -5.05M (+1194.87%) | -390.00K (-9.30%) | -430.00K (-21.82%) | -550.00K |
Net Income | -7.43M (-58.14%) | -17.75M (+251.49%) | -5.05M (+1194.87%) | -390.00K (-9.30%) | -430.00K (-21.82%) | -550.00K |
Comprehensive Income Net Of Tax | -7.81M | 48M | -6.53M (+1574.36%) | -390.00K (-9.30%) | -430.00K (-21.82%) | -550.00K |